NCT06826079View on ClinicalTrials.gov

Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2028

Conditions
Gastric Junction AdenocarcinomaGastric CancerImmunotherapyNeoadjuvant Therapies
Interventions
DRUG

Sorbitol

During the neoadjuvant treatment week, oral sorbitol 2-4g/ time, three times a day (with meals)

OTHER

Placebo

During the neoadjuvant treatment week, oral placebo 2-4g/ time, three times a day (with meals)

Trial Locations (1)

470000

RECRUITING

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER